ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy